Dnaprint Genomics Stock Net Asset
DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
DNAPrint |
DNAPrint Genomics Company Net Asset Analysis
DNAPrint Genomics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current DNAPrint Genomics Net Asset | 10.27 M |
Most of DNAPrint Genomics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, DNAPrint Genomics has a Net Asset of 10.27 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
DNAPrint Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.DNAPrint Genomics is currently under evaluation in net asset category among its peers.
DNAPrint Fundamentals
| Return On Asset | -1.05 | |||
| Profit Margin | (2.36) % | |||
| Operating Margin | (7.31) % | |||
| Current Valuation | 5.21 M | |||
| Shares Outstanding | 644.61 M | |||
| Shares Owned By Institutions | 0.18 % | |||
| Price To Sales | 0.0003 X | |||
| Revenue | 2.43 M | |||
| Gross Profit | 754.07 K | |||
| EBITDA | (5.78 M) | |||
| Net Income | (12.35 M) | |||
| Cash And Equivalents | 134.35 K | |||
| Total Debt | 240 K | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (5.78 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 24 | |||
| Beta | 23.48 | |||
| Market Capitalization | 644 | |||
| Total Asset | 10.27 M | |||
| Retained Earnings | (45.53 M) | |||
| Working Capital | (9.35 M) | |||
| Current Asset | 1.89 M | |||
| Current Liabilities | 11.24 M | |||
| Net Asset | 10.27 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in DNAPrint Stock
If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |